Correlation Between Selenium Levels in Human Tissues and HPV-related Cervical Lesions and Outcomes

NCT06665841 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-10-30

No results posted yet for this study

Summary

This study investigates the relationship between selenium levels in human tissues and the persistence of HPV (human papillomavirus) infection, particularly focusing on cervical-related lesions. The main objectives are to explore the correlation between selenium levels in different body samples (hair, nails, urine, and blood) and to evaluate selenium's potential protective effects against HPV persistence and its progression to cervical lesions.

Key goals of the study include:

Determining whether non-invasive monitoring (e.g., hair, nails, urine) can accurately reflect blood selenium levels.

Understanding how selenium levels fluctuate in women with persistent HPV infection, and whether selenium supplementation can reduce the risk of HPV-related cervical disease progression.

Exploring selenium's role in enhancing immune function, especially in older adults, to help clear HPV infection.

By recruiting volunteers for selenium level testing and tracking HPV-positive women over time, this research aims to provide evidence on the effectiveness of selenium in preventing cervical cancer progression and potentially clearing HPV infections.

Conditions

  • Cervical Intraepithelial Neoplasia (CIN)
  • Cervical Cancer
  • Persistent HPV Infection

Sponsors & Collaborators

  • Second Affiliated Hospital of Wenzhou Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2027-06-30
Completion
2027-12-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06665841 on ClinicalTrials.gov